{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T20:25:27Z","timestamp":1787430327493,"version":"build-2736575974"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Sumitomo Pharm America, Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12325-026-03669-2","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:29:45Z","timestamp":1782818985000},"page":"3765-3785","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of Persistent Storage Symptoms and Overactive Bladder in Men Diagnosed with Benign Prostatic Hyperplasia: A Narrative Review"],"prefix":"10.1007","volume":"43","author":[{"given":"Bradley C.","family":"Gill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt T.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori B.","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"3","key":"3669_CR1","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S0022-5347(17)49698-4","volume":"132","author":"SJ Berry","year":"1984","unstructured":"Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474\u20139.","journal-title":"J Urol"},{"issue":"4","key":"3669_CR2","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/JU.0000000000002183","volume":"206","author":"LB Lerner","year":"2021","unstructured":"Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I\u2013initial work-up and medical management. J Urol. 2021;206(4):806\u201317.","journal-title":"J Urol"},{"issue":"9","key":"3669_CR3","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1111\/j.1742-1241.2007.01491.x","volume":"61","author":"MT Rosenberg","year":"2007","unstructured":"Rosenberg MT, Staskin DR, Kaplan SA, MacDiarmid SA, Newman DK, Ohl DA. A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting. Int J Clin Pract. 2007;61(9):1535\u201346.","journal-title":"Int J Clin Pract"},{"issue":"1","key":"3669_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/JU.0000000000003985","volume":"212","author":"AP Cameron","year":"2024","unstructured":"Cameron AP, Chung DE, Dielubanza EJ, et al. The AUA\/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. J Urol. 2024;212(1):11\u201320.","journal-title":"J Urol"},{"issue":"6","key":"3669_CR5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s11934-013-0371-4","volume":"14","author":"MT Rosenberg","year":"2013","unstructured":"Rosenberg MT, Staskin D, Riley J, Sant G, Miner M. The evaluation and treatment of prostate-related LUTS in the primary care setting: the next STEP. Curr Urol Rep. 2013;14(6):595\u2013605.","journal-title":"Curr Urol Rep"},{"issue":"2","key":"3669_CR6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/nau.23897","volume":"38","author":"C D'Ancona","year":"2019","unstructured":"D\u2019Ancona C, Haylen B, Oelke M, et al. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol Urodyn. 2019;38(2):433\u201377.","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"3669_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000447205","volume":"11","author":"E Leron","year":"2018","unstructured":"Leron E, Weintraub AY, Mastrolia SA, Schwarzman P. Overactive bladder syndrome: evaluation and management. Curr Urol. 2018;11(3):117\u201325.","journal-title":"Curr Urol"},{"issue":"1","key":"3669_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37\u201349.","journal-title":"Urology"},{"issue":"Suppl 1","key":"3669_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1757-5672.2011.00122.x","volume":"4","author":"E Meng","year":"2012","unstructured":"Meng E, Lin WY, Lee WC, Chuang YC. Pathophysiology of overactive bladder. Low Urin Tract Symptoms. 2012;4(Suppl 1):48\u201355.","journal-title":"Low Urin Tract Symptoms"},{"issue":"Suppl 3(Suppl 3","key":"3669_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/bcpt.12626","volume":"119","author":"CH Fry","year":"2016","unstructured":"Fry CH, Vahabi B. The role of the mucosa in normal and abnormal bladder function. Basic Clin Pharmacol Toxicol. 2016;119(Suppl 3(Suppl 3)):57\u201362.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"49","key":"3669_CR11","first-page":"843","volume":"117","author":"A Miernik","year":"2020","unstructured":"Miernik A, Gratzke C. Current treatment for benign prostatic hyperplasia. Dtsch Arztebl Int. 2020;117(49):843\u201354.","journal-title":"Dtsch Arztebl Int"},{"issue":"9","key":"3669_CR12","first-page":"1559","volume":"19","author":"L Dell'Atti","year":"2015","unstructured":"Dell\u2019Atti L. Efficacy of tadalafil once daily versus fesoterodine in the treatment of overactive bladder in older patients. Eur Rev Med Pharmacol Sci. 2015;19(9):1559\u201363.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"3","key":"3669_CR13","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/iju.13489","volume":"25","author":"Y Matsukawa","year":"2018","unstructured":"Matsukawa Y, Majima T, Matsuo K, et al. Effects of tadalafil on storage and voiding function in patients with male lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a urodynamic-based study. Int J Urol. 2018;25(3):246\u201350.","journal-title":"Int J Urol"},{"issue":"3","key":"3669_CR14","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/nau.20999","volume":"30","author":"KE Andersson","year":"2011","unstructured":"Andersson KE, de Groat WC, McVary KT, et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn. 2011;30(3):292\u2013301.","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"3669_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-87505-3","volume":"11","author":"WC Lee","year":"2021","unstructured":"Lee WC, Leu S, Wu KLH, Tain YL, Chuang YC, Chan JYH. Tadalafil ameliorates bladder overactivity by restoring insulin-activated detrusor relaxation via the bladder mucosal IRS\/PI3K\/AKT\/eNOS pathway in fructose-fed rats. Sci Rep. 2021;11(1):8202.","journal-title":"Sci Rep"},{"issue":"3","key":"3669_CR16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.5213\/inj.2011.15.3.152","volume":"15","author":"KJ Cho","year":"2011","unstructured":"Cho KJ, Kang SH, Kim HS, Koh JS, Kim JC. Effect of 5-alpha reductase inhibitor on storage symptoms in patients with benign prostatic hyperplasia. Int Neurourol J. 2011;15(3):152\u20137.","journal-title":"Int Neurourol J"},{"issue":"6","key":"3669_CR17","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1590\/s1677-5538.ibju.2021.99.12","volume":"47","author":"EI Kreydin","year":"2021","unstructured":"Kreydin EI, Gomes CM, Cruz F. Current pharmacotherapy of overactive bladder. Int Braz J Urol. 2021;47(6):1091\u2013107.","journal-title":"Int Braz J Urol"},{"issue":"1","key":"3669_CR18","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s00345-025-05799-8","volume":"43","author":"B Peyronnet","year":"2025","unstructured":"Peyronnet B, Brucker BM, De Nunzio C, et al. Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes. World J Urol. 2025;43(1):514.","journal-title":"World J Urol"},{"issue":"3","key":"3669_CR19","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1152\/physrev.00038.2003","volume":"84","author":"KE Andersson","year":"2004","unstructured":"Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev. 2004;84(3):935\u201386.","journal-title":"Physiol Rev"},{"issue":"7394","key":"3669_CR20","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1136\/bmj.326.7394.841","volume":"326","author":"P Herbison","year":"2003","unstructured":"Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ. 2003;326(7394):841\u20134.","journal-title":"BMJ"},{"issue":"5","key":"3669_CR21","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1002\/nau.24348","volume":"39","author":"AL Burnett","year":"2020","unstructured":"Burnett AL, Walker DR, Feng Q, et al. Undertreatment of overactive bladder among men with lower urinary tract symptoms in the United States: a retrospective observational study. Neurourol Urodyn. 2020;39(5):1378\u201386.","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"3669_CR22","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","volume":"50","author":"DE Irwin","year":"2006","unstructured":"Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306\u201315.","journal-title":"Eur Urol"},{"issue":"6","key":"3669_CR23","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.eururo.2014.01.019","volume":"65","author":"A Agarwal","year":"2014","unstructured":"Agarwal A, Eryuzlu LN, Cartwright R, et al. What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women. Eur Urol. 2014;65(6):1211\u20137.","journal-title":"Eur Urol"},{"issue":"3","key":"3669_CR24","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1464-410X.2009.08427.x","volume":"104","author":"KS Coyne","year":"2009","unstructured":"Coyne KS, Sexton CC, Thompson CL, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int. 2009;104(3):352\u201360.","journal-title":"BJU Int"},{"issue":"4","key":"3669_CR25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/1756287209350383","volume":"1","author":"RR Dmochowski","year":"2009","unstructured":"Dmochowski RR, Gomelsky A. Overactive bladder in males. Ther Adv Urol. 2009;1(4):209\u201321.","journal-title":"Ther Adv Urol"},{"issue":"5","key":"3669_CR26","volume":"5","author":"A Stoniute","year":"2023","unstructured":"Stoniute A, Madhuvrata P, Still M, Barron-Millar E, Nabi G, Omar MI. Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2023;5(5):CD003781.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"3669_CR27","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/JU.0000000000003999","volume":"212","author":"D Staskin","year":"2024","unstructured":"Staskin D, Owens-Grillo J, Thomas E, Rovner E, Cline K, Mujais S. Efficacy and safety of vibegron for persistent symptoms of overactive bladder in men being pharmacologically treated for benign prostatic hyperplasia: results from the phase\u00a03 randomized controlled COURAGE trial. J Urol. 2024;212(2):256\u201366.","journal-title":"J Urol"},{"issue":"4","key":"3669_CR28","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.juro.2013.05.062","volume":"190","author":"VW Nitti","year":"2013","unstructured":"Nitti VW, Rosenberg S, Mitcheson DH, He W, Fakhoury A, Martin NE. Urodynamics and safety of the \u03b2\u2083-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol. 2013;190(4):1320\u20137.","journal-title":"J Urol"},{"key":"3669_CR29","unstructured":"Ng M, Leslie SW, Baradhi KM. Benign prostatic hyperplasia. StatPearls. Treasure Island: StatPearls Publishing; 2025."},{"key":"3669_CR30","unstructured":"Dougherty JM, Leslie SW, Aeddula NR. Male urinary retention: acute and chronic. StatPearls. Treasure Island: StatPearls Publishing; 2025."},{"issue":"2","key":"3669_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0022-5347(01)64508-7","volume":"158","author":"SJ Jacobsen","year":"1997","unstructured":"Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol. 1997;158(2):481\u20137.","journal-title":"J Urol"},{"issue":"4","key":"3669_CR32","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/bju.12745","volume":"115","author":"M Speakman","year":"2015","unstructured":"Speakman M, Kirby R, Doyle S, Ioannou C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)\u2014focus on the UK. BJU Int. 2015;115(4):508\u201319.","journal-title":"BJU Int"},{"issue":"6","key":"3669_CR33","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327\u201336.","journal-title":"World J Urol"},{"issue":"11","key":"3669_CR34","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1111\/j.1464-410X.2008.07601.x","volume":"101","author":"KS Coyne","year":"2008","unstructured":"Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101(11):1388\u201395.","journal-title":"BJU Int"},{"issue":"1","key":"3669_CR35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/1359105314522084","volume":"21","author":"D Kinsey","year":"2016","unstructured":"Kinsey D, Pretorius S, Glover L, Alexander T. The psychological impact of overactive bladder: a systematic review. J Health Psychol. 2016;21(1):69\u201381.","journal-title":"J Health Psychol"},{"key":"3669_CR36","unstructured":"Irwin D, Milsom I, Reilly K, et al. Men and women with overactive bladder symptoms report higher prevalence of depression and lower quality of life: results from the EPIC study. Presented at: International Continence Society, Christchurch. 2006."},{"issue":"1","key":"3669_CR37","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12894-023-01329-z","volume":"23","author":"Z Lu","year":"2023","unstructured":"Lu Z, Zhang J, Lin S, Fan Z, He Z, Tang F. Associations between overactive bladder and sleep patterns: a cross-sectional study based on 2007-2014 NHANES. BMC Urol. 2023;23(1):184.","journal-title":"BMC Urol"},{"issue":"1","key":"3669_CR38","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.eursup.2006.10.003","volume":"6","author":"I Milsom","year":"2007","unstructured":"Milsom I, Irwin D. A cross-sectional, population-based, multinational study of the prevalence of overactive bladder and lower urinary tract symptoms: results from the EPIC study. Eur Urol Suppl. 2007;6(1):4\u20139.","journal-title":"Eur Urol Suppl"},{"key":"3669_CR39","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.urology.2015.09.025","volume":"87","author":"HB Goldman","year":"2016","unstructured":"Goldman HB, Anger JT, Esinduy CB, et al. Real-world patterns of care for the overactive bladder syndrome in the United States. Urology. 2016;87:64\u20139.","journal-title":"Urology"},{"issue":"Suppl 1","key":"3669_CR40","first-page":"2","volume":"23","author":"RS Eapen","year":"2016","unstructured":"Eapen RS, Radomski SB. Gender differences in overactive bladder. Can J Urol. 2016;23(Suppl 1):2\u20139.","journal-title":"Can J Urol"},{"issue":"1","key":"3669_CR41","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.urology.2005.07.030","volume":"67","author":"F Bravi","year":"2006","unstructured":"Bravi F, Bosetti C, Dal Maso L, et al. Food groups and risk of benign prostatic hyperplasia. Urology. 2006;67(1):73\u20139.","journal-title":"Urology"},{"key":"3669_CR42","doi-asserted-by":"publisher","first-page":"1554794","DOI":"10.3389\/fnut.2025.1554794","volume":"12","author":"Y Ding","year":"2025","unstructured":"Ding Y, Mou Y, Wang D, et al. Relationship between dietary patterns and overactive bladder: a cross sectional study of NHANES 2013 to 2023. Front Nutr. 2025;12:1554794.","journal-title":"Front Nutr"},{"issue":"1","key":"3669_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-67326-w","volume":"14","author":"FA Khadour","year":"2024","unstructured":"Khadour FA, Khadour YA, Alhatem W, Al Barroush D. Risk factors associated with the severity of overactive bladder among Syrian patients with type\u00a02 diabetes. Sci Rep. 2024;14(1):16547.","journal-title":"Sci Rep"},{"issue":"7","key":"3669_CR44","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1210\/jc.2005-2799","volume":"91","author":"JK Parsons","year":"2006","unstructured":"Parsons JK, Carter HB, Partin AW, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006;91(7):2562\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"3669_CR45","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/SPV.0000000000000531","volume":"25","author":"J Zhu","year":"2019","unstructured":"Zhu J, Hu X, Dong X, Li L. Associations between risk factors and overactive bladder: a meta-analysis. Female Pelvic Med Reconstr Surg. 2019;25(3):238\u201346.","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"3669_CR46","unstructured":"Jardiance (empagliflozin). Full prescribing information. Boehringer Ingelheim Pharmaceuticals; 2023."},{"issue":"4","key":"3669_CR47","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/S0022-5347(05)00708-1","volume":"175","author":"ED Crawford","year":"2006","unstructured":"Crawford ED, Wilson SS, McConnell JD, et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol. 2006;175(4):1422\u20136.","journal-title":"J Urol"},{"issue":"4","key":"3669_CR48","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40261-021-01020-x","volume":"41","author":"MP Rutman","year":"2021","unstructured":"Rutman MP, Horn JR, Newman DK, Stefanacci RG. Overactive bladder prescribing considerations: the role of polypharmacy, anticholinergic burden, and CYP2D6 drug\u2012drug interactions. Clin Drug Investig. 2021;41(4):293\u2013302.","journal-title":"Clin Drug Investig"},{"key":"3669_CR49","unstructured":"Ditropan XL (oxybutynin chloride extended release tablets). Full Prescribing Information. 2016."},{"key":"3669_CR50","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.urology.2023.11.033","volume":"186","author":"MB Chancellor","year":"2024","unstructured":"Chancellor MB, Lucioni A, Staskin D. Oxybutynin-associated cognitive impairment: evidence and implications for overactive bladder treatment. Urology. 2024;186:123\u20139.","journal-title":"Urology"},{"issue":"1 Suppl","key":"3669_CR51","first-page":"S129","volume":"189","author":"SA Kaplan","year":"2013","unstructured":"Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol. 2013;189(1 Suppl):S129\u201334.","journal-title":"J Urol"},{"issue":"2","key":"3669_CR52","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1159\/000345050","volume":"90","author":"C Konstantinidis","year":"2013","unstructured":"Konstantinidis C, Samarinas M, Andreadakis S, Xanthis S, Skriapas K. Lower urinary tract symptoms associated with benign prostatic hyperplasia: combined treatment with fesoterodine fumarate extended-release and tamsulosin\u2014a prospective study. Urol Int. 2013;90(2):156\u201360.","journal-title":"Urol Int"},{"issue":"3","key":"3669_CR53","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.eururo.2013.03.031","volume":"64","author":"P Van Kerrebroeck","year":"2013","unstructured":"Van Kerrebroeck P, Haab F, Angulo JC, et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase\u00a02, dose-finding study (SATURN). Eur Urol. 2013;64(3):398\u2013407.","journal-title":"Eur Urol"},{"issue":"8","key":"3669_CR54","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","volume":"179","author":"CAC Coupland","year":"2019","unstructured":"Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med. 2019;179(8):1084\u201393.","journal-title":"JAMA Intern Med"},{"issue":"11","key":"3669_CR55","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1007\/s12325-018-0796-8","volume":"35","author":"SM Szabo","year":"2018","unstructured":"Szabo SM, Gooch KL, Walker DR, Johnston KM, Wagg AS. The association between overactive bladder and falls and fractures: a systematic review. Adv Ther. 2018;35(11):1831\u201341.","journal-title":"Adv Ther"},{"issue":"8","key":"3669_CR56","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1002\/nau.25037","volume":"41","author":"J Zillioux","year":"2022","unstructured":"Zillioux J, Welk B, Suskind AM, Gormley EA, Goldman HB. SUFU white paper on overactive bladder anticholinergic medications and dementia risk. Neurourol Urodyn. 2022;41(8):1928\u201333.","journal-title":"Neurourol Urodyn"},{"key":"3669_CR57","unstructured":"MYRBETRIQ\u00ae (mirabegron extended-release tablets). Full Prescribing Information. Astellas Pharma US Inc; 2021."},{"key":"3669_CR58","unstructured":"GEMTESA\u00ae (vibegron). Full Prescribing Information. Sumitomo Pharma America, Inc.; 2025."},{"issue":"2","key":"3669_CR59","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","volume":"63","author":"CR Chapple","year":"2013","unstructured":"Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase\u00a03 study to assess 12-month safety and efficacy of mirabegron, a \u03b23-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296\u2013305.","journal-title":"Eur Urol"},{"issue":"2","key":"3669_CR60","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/JU.0000000000000807","volume":"204","author":"D Staskin","year":"2020","unstructured":"Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. International phase\u00a0III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol. 2020;204(2):316\u201324.","journal-title":"J Urol"},{"issue":"7","key":"3669_CR61","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1111\/jgs.18372","volume":"71","author":"American Geriatrics Society Beers Criteria Update Expert Panel","year":"2023","unstructured":"American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052\u201381.","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"3669_CR62","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1097\/JU.0000000000000738","volume":"203","author":"SA Kaplan","year":"2020","unstructured":"Kaplan SA, Herschorn S, McVary KT, et al. Efficacy and safety of mirabegron versus placebo add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlying benign prostatic hyperplasia: a randomized, phase\u00a04 study (PLUS). J Urol. 2020;203(6):1163\u201371.","journal-title":"J Urol"},{"issue":"4","key":"3669_CR63","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.euf.2019.10.019","volume":"6","author":"H Kakizaki","year":"2020","unstructured":"Kakizaki H, Lee KS, Yamamoto O, et al. Mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: a randomized, placebo-controlled study (MATCH). Eur Urol Focus. 2020;6(4):729\u201337.","journal-title":"Eur Urol Focus"},{"issue":"5","key":"3669_CR64","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1097\/JU.0000000000001574","volume":"205","author":"D Staskin","year":"2021","unstructured":"Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. Once-daily vibegron 75\u00a0mg for overactive bladder: long-term safety and efficacy from a double-blind extension study of the international phase\u00a03 trial (EMPOWUR). J Urol. 2021;205(5):1421\u20139.","journal-title":"J Urol"},{"issue":"1","key":"3669_CR65","doi-asserted-by":"publisher","DOI":"10.1097\/JU9.0000000000000410","volume":"4","author":"D Staskin","year":"2026","unstructured":"Staskin D, Owens-Grillo J, Thomas E, Peters KM, Rovner ES, Mujais S. Safety and efficacy of vibegron in men with overactive bladder symptoms on pharmacotherapy for benign prostatic hyperplasia: results from the 28-week open-label COURAGE extension trial completing the 52-week phase\u00a03 evaluation. JU Open Plus. 2026;4(1):e00008.","journal-title":"JU Open Plus"},{"key":"3669_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/nau.70199","author":"ES Rovner","year":"2025","unstructured":"Rovner ES, Owens-Grillo J, Thomas E, et al. Bladder function and safety of Vibegron in men with overactive bladder receiving treatment for benign prostatic hyperplasia: outcomes from the phase\u00a03 randomized controlled COURAGE trial. Neurourol Urodyn. 2025. https:\/\/doi.org\/10.1002\/nau.70199.","journal-title":"Neurourol Urodyn"},{"key":"3669_CR67","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.urology.2025.08.051","volume":"206","author":"KM Peters","year":"2025","unstructured":"Peters KM, Owens-Grillo J, Thomas E, Staskin D, Rovner ES, Mujais S. Clinically meaningful improvements with vibegron in men with overactive bladder and benign prostatic hyperplasia: a responder analysis of the phase\u00a03 COURAGE trial. Urology. 2025;206:150\u20136.","journal-title":"Urology"},{"issue":"5","key":"3669_CR68","doi-asserted-by":"publisher","first-page":"300060522109817","DOI":"10.1177\/03000605221098176","volume":"50","author":"SR Kraus","year":"2022","unstructured":"Kraus SR, Li J, Kristy RM, et al. Evaluating and understanding combination therapy decision drivers for the treatment of overactive bladder in the United States. J Int Med Res. 2022;50(5):3000605221098176.","journal-title":"J Int Med Res"},{"issue":"6","key":"3669_CR69","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/j.juro.2013.05.058","volume":"190","author":"CP Filson","year":"2013","unstructured":"Filson CP, Hollingsworth JM, Clemens JQ, Wei JT. The efficacy and safety of combined therapy with alpha-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis. J Urol. 2013;190(6):2153\u201360.","journal-title":"J Urol"},{"issue":"8","key":"3669_CR70","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00228-025-03855-1","volume":"81","author":"W Huang","year":"2025","unstructured":"Huang W, Zheng X, Luo J, Chen Y, Xu Y. Comparative efficacy and adverse effects of beta3-agonists and antimuscarinics in overactive bladder: a network and component network meta-analysis. Eur J Clin Pharmacol. 2025;81(8):1217\u201327.","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"3669_CR71","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/iju.13596","volume":"25","author":"M Yoshida","year":"2018","unstructured":"Yoshida M, Kakizaki H, Takahashi S, Nagai S, Kurose T. Long-term safety and efficacy of the novel \u03b23-adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: a phase\u00a0III prospective study. Int J Urol. 2018;25(7):668\u201375.","journal-title":"Int J Urol"},{"issue":"1","key":"3669_CR72","doi-asserted-by":"publisher","first-page":"43","DOI":"10.36469\/9841","volume":"3","author":"A Wagg","year":"2015","unstructured":"Wagg A, Diles D, Berner T. Treatment patterns for patients on overactive bladder therapy: a retrospective statistical analysis using Canadian claims data. J Health Econ Outcomes Res. 2015;3(1):43\u201355.","journal-title":"J Health Econ Outcomes Res"},{"key":"3669_CR73","doi-asserted-by":"publisher","DOI":"10.1097\/01.JU.0000556186.54769.1f","volume":"201","author":"E Woff","year":"2019","unstructured":"Woff E, Cook T, Gore J, Kirby A, Gill B. PD31-05 overactive bladder in men: medication abandonment and lack of third-line therapy. J Urol. 2019;201:e567.","journal-title":"J Urol"},{"issue":"3\u20134","key":"3669_CR74","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12824","volume":"71","author":"D Sussman","year":"2017","unstructured":"Sussman D, Yehoshua A, Kowalski J, et al. Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis. Int J Clin Pract. 2017;71(3\u20134):e12824.","journal-title":"Int J Clin Pract"},{"issue":"4","key":"3669_CR75","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/luts.12382","volume":"13","author":"KV Carlson","year":"2021","unstructured":"Carlson KV, Rovner ES, Nair KV, Deal AS, Kristy RM, Hairston JC. Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: findings from the PERSPECTIVE registry study. Low Urin Tract Symptoms. 2021;13(4):425\u201334.","journal-title":"Low Urin Tract Symptoms"},{"issue":"7","key":"3669_CR76","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/nau.25478","volume":"43","author":"B Chastek","year":"2024","unstructured":"Chastek B, Carrera A, Landis C, et al. Comparative analysis of real-world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: a retrospective claims study. Neurourol Urodyn. 2024;43(7):1504\u201313.","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"3669_CR77","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.juro.2012.03.125","volume":"188","author":"EA Platz","year":"2012","unstructured":"Platz EA, Joshu CE, Mondul AM, Peskoe SB, Willett WC, Giovannucci E. Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men. J Urol. 2012;188(2):496\u2013501.","journal-title":"J Urol"},{"issue":"4","key":"3669_CR78","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/01.ede.0000219723.14476.28","volume":"17","author":"S Rohrmann","year":"2006","unstructured":"Rohrmann S, Fallin MD, Page WF, et al. Concordance rates and modifiable risk factors for lower urinary tract symptoms in twins. Epidemiology. 2006;17(4):419\u201327.","journal-title":"Epidemiology"},{"issue":"6","key":"3669_CR79","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.urology.2012.03.004","volume":"79","author":"BA Erickson","year":"2012","unstructured":"Erickson BA, Vaughan-Sarrazin M, Liu X, Breyer BN, Kreder KJ, Cram P. Lower urinary tract symptoms and diet quality: findings from the 2000-2001 National Health and Nutrition Examination Survey. Urology. 2012;79(6):1262\u20137.","journal-title":"Urology"},{"issue":"3","key":"3669_CR80","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000442866","volume":"9","author":"KV Kosilov","year":"2016","unstructured":"Kosilov KV, Loparev SA, Ivanovskaya MA, Kosilova LV. Caffeine as a probable factor for increased risk of OAB development in elderly people. Curr Urol. 2016;9(3):124\u201331.","journal-title":"Curr Urol"},{"issue":"7","key":"3669_CR81","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1046\/j.1464-410X.2002.03001.x","volume":"90","author":"R Gass","year":"2002","unstructured":"Gass R. Benign prostatic hyperplasia: the opposite effects of alcohol and coffee intake. BJU Int. 2002;90(7):649\u201354.","journal-title":"BJU Int"},{"issue":"12","key":"3669_CR82","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1093\/aje\/kws411","volume":"177","author":"NN Maserejian","year":"2013","unstructured":"Maserejian NN, Wager CG, Giovannucci EL, Curto TM, McVary KT, McKinlay JB. Intake of caffeinated, carbonated, or citrus beverage types and development of lower urinary tract symptoms in men and women. Am J Epidemiol. 2013;177(12):1399\u2013410.","journal-title":"Am J Epidemiol"},{"key":"3669_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1418117","volume":"12","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Qin W. Relationship between alcohol use and overactive bladder disease: a cross-sectional study of the NHANES 2005-2016. Front Public Health. 2024;12:1418117.","journal-title":"Front Public Health"},{"issue":"5","key":"3669_CR84","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.juro.2017.04.097","volume":"198","author":"CS Bradley","year":"2017","unstructured":"Bradley CS, Erickson BA, Messersmith EE, et al. Evidence of the impact of diet, fluid intake, caffeine, alcohol and tobacco on lower urinary tract symptoms: a systematic review. J Urol. 2017;198(5):1010\u201320.","journal-title":"J Urol"},{"issue":"2","key":"3669_CR85","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.juro.2012.03.128","volume":"188","author":"NN Maserejian","year":"2012","unstructured":"Maserejian NN, Kupelian V, Miyasato G, McVary KT, McKinlay JB. Are physical activity, smoking and alcohol consumption associated with lower urinary tract symptoms in men or women? Results from a population based observational study. J Urol. 2012;188(2):490\u20135.","journal-title":"J Urol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03669-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03669-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03669-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T20:01:37Z","timestamp":1787428897000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03669-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":85,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3669"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03669-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Bradley C. Gill is a consultant for Boston Scientific and Sumitomo Pharma America, and an investigator in research studies for Boston Scientific. Matt T. Rosenberg is an advisor to and meeting participant\/lecturer for Astellas and Sumitomo Pharma America, Inc. He is a meeting participant\/lecturer for Ferring. Steven A. Kaplan is a consultant for Boston Scientific. Lori B. Lerner is a consultant for Boston Scientific and Sumitomo Pharma America; on regulatory committees for Proverum and ALPFA; and an investigator in research studies funded by Boston Scientific, Teleflex, and Janssen.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}